ClinicalTrials.gg
Drug

PM 01183 clinical trials

Also written Lurbinectedin, PM01183 and Zepzelca.

studies test it
53
open now
17
in phase 3
7
first study started
2009

How each study uses PM 01183 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the PM 01183 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Jun 2020 · ZEPZELCA · NDA 213702 (FDA, Drugs@FDA)
European Union
29 May 2026 · Zepzelca · EMEA/H/C/006673 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

lurbinectedin (PM01183)
9
Lurbinectedin 4 MG Injection [Zepzelca]
2

Brand

Zepzelca
8
Zepsyre
1

Development codes

PM01183
18
JZP712
1
PM1183
1

Other names

Lurbinectedin
31

Studies by the year they started

52 studies that test it; most in 2023 (7); 1 more planned to start later

Studies that test PM 01183, by start year
YearStudies
20091
20114
20121
20133
20141
20155
20162
20171
20191
20205
20214
20226
20237
20244
20255
20262

By phase

A phase 1/2 study counts in both.

Phase 1
28
Phase 2
31
Phase 3
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 27 · Other 26

PharmaMar (20) · Jazz Pharmaceuticals (3) · Massachusetts General Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Luye Pharma Group Ltd. (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (1) · Hoffmann-La Roche (1)

Often tested with

Tested in the same studies.

Irinotecan (6) · Topotecan (3) · Paclitaxel (3) · Durvalumab (2) · Etoposide (2) · Carboplatin (2) · Nivolumab (2) · Bosentan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

PM 01183 is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 7

Studies that test PM 01183.

Studies

Open first, then newest update. How each study uses PM 01183 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 53

See all 53 studies that test PM 01183 →

Given beside what is tested · 6 — PM 01183 is usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with PM 01183

Codes

What other systems call PM 01183 · ClinicalTrials.gg INT005937

  • MeSH (NLM) C568606PM 01183One source ClinicalTrials.gov
  • RxNorm 2374729One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.